ClinicalTrials.govpublic full text
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
oropharyngeal squamous cell carcinoma, throat, head and neck cancer, squamous cell cancer, opscc, hnscc, human papillomavirus, hpv, immunotherapy, real-world study, pd-l1 therapy, checkpoint inhibitor
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 863188
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.